Catalog No.
Product Name
Application
Product Information
Citations
-
TbrPDEB1 Inhibitor
Pyrazole N-Desmethyl sildenafil functions as an inhibitor of Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1). It demonstrates approximately 16% inhibition at a concentration of 100 µM. This compound is relevant for research into the pharmacological targeting of TbrPDEB1, which plays a role in the pathogenicity of Trypanosomiasis. -
PDE4 Inhibitor
AWD 12-281 is a potent and selective inhibitor of phosphodiesterase 4 (PDE4), with an IC50 of 9.7 nM. This compound demonstrates significant anti-inflammatory activity and is primarily utilized in research focused on allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Its oral bioavailability facilitates in vivo studies of PDE4 modulation in various inflammatory diseases. -
PDE Inhibitor
MP 518 is a phosphodiesterase (PDE) inhibitor that exhibits antihypertensive properties. By inhibiting the degradation of cyclic adenosine monophosphate (cAMP), MP 518 facilitates an increase in intracellular calcium (ICa) levels and antagonizes β-adrenergic stimulation, leading to vasodilation. This compound is valuable for research in cardiovascular biology and the mechanisms underlying hypertension. -
PDE Inhibitor
Pimobendan hydrochloride is a selective phosphodiesterase 3 (PDE3) inhibitor, with an IC50 value of 0.32 μM. It enhances cardiac contractility and promotes vasodilation, making it relevant for research into heart failure and other cardiovascular conditions. This compound can be utilized in studies exploring the modulation of cAMP levels and its effects on cardiac performance. -
Phosphodiesterase (PDE) Inhibitor
Dipyridamole Mono-O-β-D-glucuronide is an O-glucuronide derivative of Dipyridamole, a well-known phosphodiesterase (PDE) inhibitor. This compound exhibits significant inhibitory activity against PDE, which can influence cellular signaling pathways. Dipyridamole Mono-O-β-D-glucuronide is primarily utilized in research exploring drug metabolism and transport mechanisms, as well as in studies assessing the therapeutic potential of PDE inhibition. -
PDE11A Modulator
PDE11A modulator-1 is a selective modulator targeting phosphodiesterase 11A (PDE11A). This compound enhances intracellular cAMP levels, thereby influencing various signaling pathways. It has potential applications in the study of metabolic disorders and neurological conditions linked to cAMP signaling. PDE11A modulator-1 serves as a valuable tool for researchers investigating the role of PDE11A in cellular processes and therapeutic development. -
PDE IV Inhibitor
RS14203 is a potent inhibitor of phosphodiesterase type IV (PDE IV), which plays a crucial role in the regulation of cyclic nucleotide signaling. This compound is known to induce emesis, making it valuable in research focused on gastrointestinal function and the emetic response. Its application extends to investigations of PDE IV's involvement in various physiological processes and the development of therapeutic strategies targeting cyclic nucleotide pathways. -
PDE2 Inhibitor
BML-288 is a potent inhibitor of phosphodiesterase 2 (PDE2) with an IC50 value of 40 nM. This compound demonstrates significant biological activity in modulating cyclic nucleotide levels, making it relevant for research into osteoarthritis pain and related conditions. Its ability to selectively inhibit PDE2 provides valuable insights into cellular signaling pathways and therapeutic targets in inflammatory and pain-related disorders. -
Phosphodiesterase (PDE)
Oxagrelate is a selective inhibitor of cyclic adenosine monophosphate phosphodiesterase (PDE). It demonstrates concentration-dependent inhibition of platelet aggregation induced by collagen and adenosine diphosphate (ADP) in vitro. This compound is valuable for research applications focused on platelet activation, hemostasis, and thrombotic disorders. -
PDE5 Inhibitor
UK-371800 is a highly selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 of 4.2 nM. This compound demonstrates favorable permeability characteristics and remains unaffected by P-glycoprotein efflux mechanisms. UK-371800 is primarily utilized in research applications related to erectile dysfunction and pulmonary hypertension, contributing to the understanding of cGMP signaling pathways in cardiovascular health. -
PDE Inhibitor
PDE-IN-3 is a phosphodiesterase (PDE) inhibitor exhibiting an IC50 value of 260 μM. This compound effectively modulates the breakdown of cyclic nucleotides, making it a valuable tool for investigating intracellular signaling pathways. PDE-IN-3 is applicable in research areas such as cardiovascular biology, neurobiology, and cancer research, where PDE inhibitors play a critical role in therapeutic strategies. -
PDE5 Inhibitor
UK 357903 is a selective inhibitor of phosphodiesterase 5 (PDE5), exhibiting IC50 values of 1.7 nM for PDE5 and 714 nM for PDE6. This compound demonstrates significant vasodilatory effects in mesenteric and hindlimb vascular beds, making it a promising candidate for research applications related to erectile dysfunction and vascular smooth muscle relaxation. Its mechanism of action provides a valuable tool for investigating PDE5-related pathways in various physiological and pathological contexts. -
PDE4 Inhibitor
PDE4-IN-25 is a potent phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 value of 0.1 μM. This compound is significant in the study of inflammatory diseases, as it regulates intracellular cyclic nucleotide levels, thereby influencing inflammatory response pathways. PDE4-IN-25 is valuable for researchers investigating therapeutic interventions for conditions characterized by dysregulated inflammation. -
PDE4 Inhibitor
LEO 29102 is a potent inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 5 nM. This compound effectively inhibits the release of TNFα, making it a valuable tool for studies related to inflammatory responses. LEO 29102 shows promise in the research of atopic dermatitis and other related conditions associated with PDE4 activity. -
Cyclic AMP-PDE Inhibitor
2'-O-MB-cGMP sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I50 value of 35 µM. It effectively inhibits the hydrolysis of cyclic nucleotides by Ca2+-dependent phosphodiesterases, utilizing cAMP or cGMP as substrates. This compound is invaluable in research focused on cyclic nucleotide signaling pathways and can aid in the study of vascular smooth muscle function, platelet aggregation, and a range of physiological processes influenced by cyclic GMP. -
PDE5 Inhibitor
T-0156 free base is a selective inhibitor of phosphodiesterase type 5 (PDE5), functioning through competitive inhibition of cyclic guanosine monophosphate (cGMP) hydrolysis, with an IC50 of 0.23 nM. In addition to its primary target, T-0156 exhibits some inhibitory activity against PDE6 with an IC50 of 56 nM, while demonstrating low potency against other PDEs, including PDE1, PDE2, PDE3, and PDE4 (IC50 > 10 μM). This compound plays a valuable role in enhancing the nitric oxide (NO)/cGMP signaling pathway, making it suitable for research in vascular biology and therapies related to erectile dysfunction and pulmonary hypertension. -
PDE Inhibitor
Irsogladine maleate is a phosphodiesterase 4 (PDE4) inhibitor that enhances intracellular cyclic adenosine monophosphate (cAMP) levels. This compound exhibits anti-inflammatory properties and is primarily utilized in research focused on chronic inflammatory diseases and gastric protection mechanisms. Additionally, its affinity for muscarinic acetylcholine receptors may provide insights into neuroprotective effects and gastrointestinal motility studies. -
PDE III Inhibitor
Adibendan (BM 14478) is a selective phosphodiesterase III (PDE III) inhibitor, exhibiting an IC50 value of 2.0 μM. With over 60-fold selectivity compared to PDE I and II inhibitors, Adibendan functions as a novel cardiotonic agent. This compound is valuable for researchers investigating cardiovascular diseases and exploring the modulation of cardiac contractility through PDE III inhibition. -
PDE10A Inhibitor
Mardepodect precursor is the chemical precursor of Mardepodect, a selective inhibitor targeting phosphodiesterase 10A (PDE10A). This compound exhibits potent inhibitory activity with an IC50 of 0.37 nM and displays greater than 1000-fold selectivity over other phosphodiesterases. Mardepodect and its precursor are integral for research into neuropsychiatric disorders, promoting the understanding of PDE10A's role in central nervous system functions. -
PDE Inhibitor
LY 186126 is a potent phosphodiesterase (PDE) inhibitor that acts by targeting cardiac sarcoplasmic reticulum PDE with a high binding affinity (Kd = 5.6 nM). This compound is utilized in research related to cardiac function and signaling pathways by modulating cyclic nucleotide levels, making it valuable for studies on cardiovascular conditions and PDE-related mechanisms. -
PDE Inhibitor
Quazodine is a potent phosphodiesterase (PDE) inhibitor that modulates intracellular cAMP and cGMP levels. Its primary activity involves vasodilatory effects, making it a valuable tool in studies related to vascular smooth muscle function. Quazodine is suitable for research applications exploring cardiovascular diseases and smooth muscle physiology. -
Phosphodiesterase (PDE) Inhibitor
K-252d is an indolocarbazole alkaloid that acts primarily as a phosphodiesterase (PDE) inhibitor. It demonstrates significant inhibitory activity against calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart, with an IC50 of 46.2 μM, and is also recognized for its role as a protein kinase C (PKC) inhibitor, exhibiting an IC50 of 350 nM against PKC isolated from rat brain. This compound is valuable for studies related to signal transduction pathways and therapeutic interventions targeting PDE-related disorders. -
PDE Stabilizer
6-Cl-cPuMP sodium is a cAMP analog that acts as a phosphodiesterase (PDE) stabilizer. This compound exhibits excellent membrane permeability, allowing for effective cellular uptake, while maintaining stability against PDE degradation. 6-Cl-cPuMP sodium is particularly useful in research related to the nervous system, enabling studies of cAMP signaling pathways and their implications in neurobiology. -
PDE4 Inhibitor
Cipamfylline is a potent inhibitor of phosphodiesterase 4 (PDE4), specifically facilitating the accumulation of PDE4A4 within distinct cellular regions via its interaction with the ubiquitin scaffolding protein p62. This compound plays a critical role in research focused on atopic dermatitis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions in this condition. -
PDE4 Inhibitor
ONO-6126 is a selective phosphodiesterase 4 (PDE4) inhibitor with potential therapeutic applications in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By inhibiting PDE4, it increases intracellular cAMP levels, which can help reduce inflammation and bronchoconstriction. This compound is valuable for research focused on understanding the molecular mechanisms of respiratory conditions and testing novel therapeutic strategies. -
PDE4 Inhibitor
Braylin is a potent phosphodiesterase-4 (PDE4) inhibitor that plays a significant role in anti-inflammatory and immunomodulatory processes. It is particularly relevant in the exploration of immunoinflammatory diseases, making it a valuable tool for researchers studying these conditions. Its ability to modulate inflammatory responses positions it as a potential therapeutic target in related research applications. -
PDE4 Inhibitor
RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4), which plays a crucial role in the degradation of cyclic adenosine monophosphate (cAMP). By inhibiting PDE4 activity, RS-25344 promotes increased intracellular cAMP levels, contributing to an array of biological responses. This compound is valuable for research in inflammation, immune disorders, neurodegenerative diseases, and cardiovascular conditions. Its ability to modulate cAMP signaling makes it a significant tool for exploring therapeutic strategies in these areas. -
PDE5 Inhibitor
Desmethyl thiosildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. This compound exhibits significant biological activity by promoting vasodilation through the inhibition of PDE5, thereby enhancing nitric oxide signaling. It is commonly used in research applications focused on cardiovascular function and erectile dysfunction, providing insights into the therapeutic potential for related disorders. -
PDE5 Inhibitor
JNJ-10258859 is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, exhibiting a Ki value of 0.23 nM. This compound effectively elevates cyclic GMP levels, which is crucial for promoting smooth muscle relaxation and improving erectile function. JNJ-10258859 is primarily utilized in research focused on erectile dysfunction and related cardiovascular studies. -
PDE2 Agonist
5,6-DM-cBIMP is a cyclic nucleotide analog that serves as an agonist for phosphodiesterase 2 (PDE2). It is capable of significantly enhancing the hydrolytic activities of cAMP and cGMP by PDE2, making it a valuable tool for researchers investigating the modulation of cyclic nucleotide signaling pathways. Its application is particularly relevant in studies focused on cardiovascular and neurological research. -
PDE1 Inhibitor
MMPX is a potent phosphodiesterase type 1 (PDE1) inhibitor that modulates intracellular signaling pathways by increasing cyclic nucleotide levels. This compound exhibits significant biological activity in various cellular processes, making it a valuable tool for studying the physiological roles of PDE1 in neurological and cardiovascular research. Its application extends to exploring therapeutic strategies for diseases associated with dysregulated cyclic nucleotide signaling. -
PDE5 Inhibitor
BMS-341400 mesylate is a selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 0.3 nM. This compound attenuates the degradation of cyclic guanosine monophosphate (cGMP), thereby facilitating nitric oxide (NO)-induced relaxation of corpus cavernosum smooth muscle and enhancing erectile function. BMS-341400 mesylate serves as a valuable tool for investigating mechanisms underlying erectile dysfunction. -
KRAS-PDEδ Inhibitor
NHTD is a selective inhibitor of KRAS-PDEδ, targeting the prenyl-binding pocket of PDEδ and modulating the cellular localization of KRAS. This action effectively inhibits the proliferation of KRAS-mutant cancer cells and promotes apoptosis. NHTD is a valuable tool for investigations into KRAS-driven non-small cell lung cancer (NSCLC) and related oncology research. -
Phosphodiesterase (PDE) Inhibitor
Saterinone is a phosphodiesterase III (PDE III) inhibitor that enhances intracellular cAMP levels, leading to increased vasodilation and improved cardiac function. This compound is significant in cardiovascular research, particularly in studies focused on heart failure and angina. Its role in modulating cAMP signaling pathways makes it an important tool for exploring therapeutic strategies in cardiovascular diseases. -
Phosphodiesterase (PDE) Inhibitor
PDE IV-IN-1 is a selective inhibitor of phosphodiesterase IV (PDE4), an enzyme involved in the degradation of cyclic AMP. This compound exhibits anti-inflammatory properties, making it valuable for the research of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as other inflammatory diseases. Its ability to modulate cAMP levels positions PDE IV-IN-1 as a significant tool in the study of inflammatory signaling pathways. -
Phosphodiesterase (PDE) Inhibitor
L791943 is a selective phosphodiesterase-4 (PDE4) inhibitor, demonstrating a potent inhibitory effect with an IC50 value of 4.2 nM. This compound is primarily utilized in research aimed at understanding the role of PDE4 in various inflammatory and neurological disorders. Its efficacy in modulating cyclic nucleotide levels makes it a valuable tool for studying signal transduction pathways and therapeutic interventions. -
Phosphodiesterase (PDE) Inhibitor
Sch59498 is a potent inhibitor of phosphodiesterase 1C (PDE1C), a phosphodiesterase enzyme involved in cellular signal transduction through the hydrolysis of cyclic nucleotides. This compound demonstrates significant effects on intracellular cAMP and cGMP levels, thereby influencing various physiological processes. Sch59498 is primarily utilized in research applications focused on cardiovascular diseases, neuroprotection, and cancer biology, providing insights into the modulation of signaling pathways associated with these conditions. -
Phosphodiesterase (PDE) Inhibitor
Win-62005 is a potent inhibitor of cyclic AMP phosphodiesterase III (PDE III), exhibiting Ki values of 25 nM for rat heart and 26 nM for canine aorta. This compound is primarily utilized in cardiovascular research to explore its effects on cAMP signaling pathways and its potential therapeutic applications in heart conditions. Through the inhibition of PDE III, Win-62005 enhances intracellular cAMP levels, thereby influencing myocardial contractility and vascular tone. -
Cathepsin A Substrate
FA-Phe-Phe is a furylacryloyl (fa)-amino acid derivative that serves as a specific substrate for Cathepsin A. This compound is valuable in elucidating the enzymatic activity and functional mechanisms of Cathepsin A, contributing to research on its role in physiological and pathological processes. FA-Phe-Phe is particularly useful in studies involving enzymatic assays and screening for potential inhibitors or modulators of Cathepsin A. -
PKCα Inhibitor
Leucosceptoside A is a phenylethanoid glycoside that functions as a selective inhibitor of Protein Kinase C alpha (PKCα). This compound demonstrates significant anti-hyperglycemic and anti-hypertensive effects and exhibits inhibitory activity against α-glucosidase, with an IC50 value of 19.0 μM. Leucosceptoside A is relevant for research into metabolic disorders and cardiovascular diseases, providing insights into therapeutic approaches targeting PKCα. -
Fluorochrome
DDAO phosphate diammonium is a fluorescent phosphatase substrate that serves as a sensitive probe for enzyme activity. With tunable excitation wavelengths ranging from 600 to 650 nm and a long emission wavelength of 656 nm, it facilitates the detection of various enzymes including β-galactosidase, sulfatase, protein phosphatase 2A, carboxylesterase 2, human albumin, and esterase. This reagent is ideal for applications in enzymology and biochemistry research, enabling real-time monitoring of enzyme activities in different biological systems. -
TrxR Fuorescence Probe
Seph-PAO is a modified para-aminooxyphenyl (PAO) compound conjugated with a sepharose fluorophore, designed to selectively detect thioredoxin reductase (TrxR). This fluorescence probe demonstrates high sensitivity and specificity, facilitating the study of TrxR activity in various biological systems. Researchers can employ Seph-PAO in investigations of oxidative stress, redox signaling, and the role of TrxR in cellular processes. -
Carboxylesterase Substrate, Mitochondria Targeting Agent
CEMT is a selective substrate for carboxylesterases, functioning as a ratiometric two-photon fluorescent reporter probe. Upon hydrolysis by carboxylesterases, CEMT generates HMT, which facilitates mitochondrial pH sensing through ratiometric fluorescence changes in response to pH fluctuations. This compound specifically targets and covalently binds to mitochondria, minimizing leakage during acidification, thereby enabling in situ imaging of mitochondrial dynamics and pH variations within biological systems. -
CYP1B1
CYP1B1-IN-6 is a selective inhibitor of the cytochrome P450 enzyme CYP1B1. This compound demonstrates the ability to inhibit CYP1B1 activity, making it useful for tumor identification in fluorescence and photoacoustic imaging modalities. CYP1B1-IN-6 can assist in research applications focused on cancer diagnostics and the investigation of metabolic processes involving CYP1B1. -
ALOX12-ACC1 interaction inhibitor
IMA-1 is an inhibitor of the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). This compound has demonstrated significant efficacy in blocking the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, while not inducing hyperlipidemia. IMA-1 serves as a valuable tool for investigating the underlying mechanisms and potential treatments for NASH. -
Herbicide
Sethoxydim is a postemergent herbicide that specifically targets acetyl-coenzyme A carboxylase (ACCase) activity in plants. By inhibiting this key enzyme, Sethoxydim effectively disrupts fatty acid biosynthesis, leading to the control of various grass weeds in a range of crop systems. This compound is widely utilized in agricultural research to study herbicide resistance mechanisms and weed management strategies. -
Herbicide
Haloxyfop is an aryloxyphenoxypropionic acid herbicide that primarily targets acetyl coenzyme A carboxylase (EC 6.4.1.2) in corn seedling chloroplasts, exhibiting an IC50 value of 0.5 μM. This compound effectively controls grass weeds in broad-leaf crops, making it a valuable tool in agricultural research. Its selective action enhances studies on herbicide resistance and crop management strategies. -
Herbicide
Quizalofop is a selective herbicide that targets acetyl-CoA carboxylase (ACCase), leading to the inhibition of fatty acid synthesis in plants. This compound is instrumental in agricultural research and can be utilized to screen EMS mutated microalgae, facilitating investigations aimed at enhancing microalgae biofuel production efficiency.
-
Herbicide
Quizalofop-P is a selective herbicide that targets the inhibition of cellular fatty acid synthesis in plants. It is effectively absorbed through the leaves and stems of weed species, leading to upward and downward translocation and accumulation in meristematic regions. This compound induces necrosis in grass weeds while exhibiting minimal impact on dicotyledonous crops, making it a valuable tool in agricultural applications for effective weed management. -
Herbicide
Fluazifop is a selective herbicide that functions by inhibiting acetyl-CoA carboxylase, an enzyme critical for fatty acid synthesis in plants. This inhibition disrupts the growth of specific grass species while sparing broadleaf plants, making it valuable in agricultural applications for weed management. Fluazifop is particularly effective in controlling post-emergent grass weeds, contributing to improved crop yields and sustainable farming practices.
